Related Experiment Video

Updated: Nov 14, 2025

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells
06:29

Real-Time Monitoring of Aurora kinase A Activation using Conformational FRET Biosensors in Live Cells

Published on: July 30, 2020

3.3K

Aurora Kinase B Expression, Its Regulation and Therapeutic Targeting in Human Retinoblastoma

Naheed Arfin Borah1,2, Swatishree Sradhanjali1,2, Manas Ranjan Barik1

  • 1The Operation Eyesight Universal Institute for Eye Cancer, LV Prasad Eye Institute, Bhubaneswar, India.

Investigative Ophthalmology & Visual Science
|March 11, 2021
PubMed
Abstract

Insights

Aurora kinase B (AURKB) is overexpressed in retinoblastoma (RB), a type of eye cancer. Targeting AURKB with inhibitors reduces tumor cell growth, offering a potential new therapy for RB patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Aurora kinase B (AURKB) is crucial for mitosis and a recognized cancer therapeutic target.
  • The role of AURKB in retinoblastoma (RB), a pediatric eye cancer, remains uninvestigated.

Purpose of the Study:

  • To investigate the role of AURKB in retinoblastoma.
  • To determine the regulatory mechanisms of AURKB expression in RB.
  • To evaluate AURKB as a potential therapeutic target for RB.

Main Methods:

  • Immunohistochemistry and immunoblotting to assess AURKB protein expression in RB tissues and cell lines.
  • Pharmacological inhibition and shRNA knockdown to analyze AURKB's impact on RB cell viability, apoptosis, and cell cycle.
  • Chromatin immunoprecipitation-qPCR to confirm MYCN binding to the AURKB promoter.

Main Results:

  • AURKB expression is significantly elevated in human RB tissues, correlating with tumor invasion.
  • Inhibition of AURKB reduces RB cell survival, induces apoptosis, and causes G2/M cell cycle arrest.
  • Primary RB specimens demonstrate reduced cell viability upon AURKB inhibition.
  • The MYCN oncogene was identified as a regulator of AURKB expression in RB.

Conclusions:

  • AURKB is overexpressed in retinoblastoma.
  • Targeting AURKB presents a promising novel therapeutic strategy to inhibit retinoblastoma tumor growth.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.4K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.1K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
16.1K